Connect Biopharma Holdings Ltd
NASDAQ:CNTB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.94
2.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd
Accumulated Depreciation
Connect Biopharma Holdings Ltd
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
Accumulated Depreciation
-¥3.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accumulated Depreciation
-¥2B
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accumulated Depreciation
-¥787.8m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accumulated Depreciation
-¥1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Accumulated Depreciation
-¥159.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
Connect Biopharma Holdings Ltd
Glance View
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
See Also
What is Connect Biopharma Holdings Ltd's Accumulated Depreciation?
Accumulated Depreciation
-3.1m
CNY
Based on the financial report for Dec 31, 2023, Connect Biopharma Holdings Ltd's Accumulated Depreciation amounts to -3.1m CNY.
What is Connect Biopharma Holdings Ltd's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-19%
Over the last year, the Accumulated Depreciation growth was 79%. The average annual Accumulated Depreciation growth rates for Connect Biopharma Holdings Ltd have been -4% over the past three years , -19% over the past five years .
You don't have any saved screeners yet
